Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Lucia, Campos Carrascosa"'
Autor:
Daniel Snell, Tea Gunde, Stefan Warmuth, Bithi Chatterjee, Matthias Brock, Christian Hess, Maria Johansson, Alexandre Simonin, Fabio Mario Spiga, Christopher Weinert, Niels Kirk, Nicole Bassler, Lucia Campos Carrascosa, Naomi Flückiger, Robin Heiz, Sandro Wagen, Noreen Giezendanner, Alessandra Alberti, Yasemin Yaman, Dana Mahler, Dania Diem, Peter Lichtlen, David Urech
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTMesothelin (MSLN) is an attractive immuno-oncology target, but the development of MSLN-targeting therapies has been impeded by tumor shedding of soluble MSLN (sMSLN), on-target off-tumor activity, and an immunosuppressive tumor microenvironme
Externí odkaz:
https://doaj.org/article/37427098ffe74543b7338afdbca88496
Autor:
Daniel Snell, Niels Kirk, David Urech, Nicole Bassler, Lucia Campos Carrascosa, Pawel Chrom, Peter Lichtlen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/c315729799aa4b2f93a1e6b1122a687a
Autor:
Yannick S. Rakké, Lucia Campos Carrascosa, Adriaan A. van Beek, Valeska de Ruiter, Rachelle S. van Gemerden, Michail Doukas, Pascal G. Doornebosch, Maarten Vermaas, Susan ter Borg, Erwin van der Harst, Peter Paul L.O. Coene, Mike Kliffen, Dirk J. Grünhagen, Cornelis Verhoef, Jan N.M. IJzermans, Jaap Kwekkeboom, Dave Sprengers
Publikováno v:
Cellular and Molecular Gastroenterology and Hepatology, Vol 15, Iss 1, Pp 77-97 (2023)
Background & Aims: In contrast to mismatch repair deficient colorectal carcinoma (CRC), MMR proficient (pMMR) CRC does not respond to immune checkpoint blockade. We studied immune checkpoint stimulation via glucocorticoid-induced tumor necrosis facto
Externí odkaz:
https://doaj.org/article/4a888c4532714648a65f508089f7a907
Autor:
Zhouhong Ge, Guoying Zhou, Lucia Campos Carrascosa, Erik Gausvik, Patrick P.C. Boor, Lisanne Noordam, Michael Doukas, Wojciech G. Polak, Türkan Terkivatan, Qiuwei Pan, R. Bart Takkenberg, Joanne Verheij, Joris I. Erdmann, Jan N.M. IJzermans, Maikel P. Peppelenbosch, Jaco Kraan, Jaap Kwekkeboom, Dave Sprengers
Publikováno v:
Cellular and Molecular Gastroenterology and Hepatology, Vol 12, Iss 2, Pp 443-464 (2021)
Background & Aims: TIGIT is a co-inhibitory receptor, and its suitability as a target for cancer immunotherapy in HCC is unknown. PD1 blockade is clinically effective in about 20% of advanced HCC patients. Here we aim to determine whether co-blockade
Externí odkaz:
https://doaj.org/article/89506260ed7f4f479d3b7d6501af3e38
Autor:
Christina Lückel, Felix Picard, Hartmann Raifer, Lucia Campos Carrascosa, Anna Guralnik, Yajuan Zhang, Matthias Klein, Stefan Bittner, Falk Steffen, Sonja Moos, Federico Marini, Renee Gloury, Florian C. Kurschus, Ying-Yin Chao, Wilhelm Bertrams, Veronika Sexl, Bernd Schmeck, Lynn Bonetti, Melanie Grusdat, Michael Lohoff, Christina E. Zielinski, Frauke Zipp, Axel Kallies, Dirk Brenner, Michael Berger, Tobias Bopp, Björn Tackenberg, Magdalena Huber
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-15 (2019)
Dimethyl fumarate (DMF) is a therapy for multiple sclerosis (MS) with undetermined mechanism of action. Here the authors find that clinical response to DMF associates with decrease in IL-17-producing CD8+ T cells (Tc17), delineate molecular pathways
Externí odkaz:
https://doaj.org/article/2e2f0c2356834c5db881aabfe09b997c
Autor:
Maik Luu, Sabine Pautz, Vanessa Kohl, Rajeev Singh, Rossana Romero, Sébastien Lucas, Jörg Hofmann, Hartmann Raifer, Niyati Vachharajani, Lucia Campos Carrascosa, Boris Lamp, Andrea Nist, Thorsten Stiewe, Yoav Shaul, Till Adhikary, Mario M. Zaiss, Matthias Lauth, Ulrich Steinhoff, Alexander Visekruna
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-12 (2019)
Short-chain fatty acids (SCFAs) have immunomodulatory effects, but the underlying mechanisms are still unclear. Here the authors show that a SCFA, pentanoate, suppresses autoimmune inflammation in mouse models of colitis and multiple sclerosis via ep
Externí odkaz:
https://doaj.org/article/d856e522710041fdbeadd9b5689c49a8
Autor:
Jie Wei, Shahram Salek-Ardakani, Wenjing Yang, Lucia Campos Carrascosa, Adriaan A van Beek, Valeska de Ruiter, Michail Doukas, Timothy S Fisher, Keith Ching, Karlijn van Loon, Patrick P C Boor, Yannick S Rakké, Lisanne Noordam, Pascal Doornebosch, Dirk Grünhagen, Kees Verhoef, Wojciech G Polak, Jan N M IJzermans, Irene Ni, Yik Andy Yeung, Dave Sprengers, Jaap Kwekkeboom
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background OX40 (CD134) is a costimulatory molecule of the tumor necrosis factor receptor superfamily that is currently being investigated as a target for cancer immunotherapy. However, despite promising results in murine tumor models, the clinical e
Externí odkaz:
https://doaj.org/article/e56e3eb9973e485888dbd8bd5af2b0dc
Autor:
Lucia Campos Carrascosa, Matthias Klein, Yohko Kitagawa, Christina Lückel, Federico Marini, Anika König, Anna Guralnik, Hartmann Raifer, Stefanie Hagner-Benes, Diana Rädler, Andreas Böck, Cholho Kang, Michael Lohoff, Holger Garn, Bianca Schaub, Friederike Berberich-Siebelt, Shimon Sakaguchi, Tobias Bopp, Magdalena Huber
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-12 (2017)
IFN-γ signalling inhibits production of IL-9, the defining cytokine of the Th9 cell subset. Here the authors show that IFN-γ does this by driving IRF1 to compete with IRF4 forIl9promoter binding and skewing these cells towards a Th1 phenotype, an e
Externí odkaz:
https://doaj.org/article/13172fb84a7445059a0849047683d7fa
Autor:
Ivana Djuretic, Dave Tsao, Yuanming Xu, Lucia Campos Carrascosa, Gabriel R. Starbeck-Miller, Valeska de Ruiter, Wenjing Yang, Javier Chaparro-Riggers, Zhouhong Ge, Changhua Ji, Tina Mistry, Jaap Kwekkeboom, Lidia Mosyak, John Zeytounian, Matthew Ling-Hon Chu, Renny Feldman, Lisanne Noordam, Eugenia Kraynov, Tzu-Hsuan Huang, Martin E. van Royen, Diamanda Rigas, Sherman M. Chin, Irene Ni, Dave Sprengers, Shih-Hsun Chen, Danielle Pappas, Kevin Lindquist, Michael Doukas, Patrick P.C. Boor, Joanne Verheij, Keith A. Ching, Magdalena Dorywalska, Luz Marina Londono, Joris I. Erdmann, Dirk J. Grünhagen, Laura Lin, Bing Kuang, Jan N. M. IJzermans, Yik Andy Yeung, James Patterson, Jie Guo, Salah Mahmoudi, Terrence Park, Pascal G. Doornebosch, Robert C Rickert
Publikováno v:
Cancer Immunology Research, 9(10), 1141-1157. American Association for Cancer Research Inc.
Cancer immunology research, 9(10), 1141-1157. American Association for Cancer Research Inc.
Cancer immunology research, 9(10), 1141-1157. American Association for Cancer Research Inc.
The use of cytokines for immunotherapy shows clinical efficacy but is frequently accompanied by severe adverse events caused by excessive and systemic immune activation. Here, we set out to address these challenges by engineering a fusion protein of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::314114dc45d8eb706b8d4a6ebcec02a6
https://doi.org/10.1158/2326-6066.cir-21-0058
https://doi.org/10.1158/2326-6066.cir-21-0058
Autor:
Guoying Zhou, Ruby Lieshout, Gilles S. van Tienderen, Valeska de Ruiter, Martin E. van Royen, Patrick P. C. Boor, Luc Magré, Jyaysi Desai, Kübra Köten, Yik Yang Kan, Zhouhong Ge, Lucia Campos Carrascosa, Cecile Geuijen, Dave Sprengers, Luc J. W. van der Laan, Monique M. A. Verstegen, Jaap Kwekkeboom
Publikováno v:
British Journal of Cancer, 127(4), 649-660. Nature Publishing Group
Background Immunotherapy with immune checkpoint inhibitors (ICIs) is being explored to improve cholangiocarcinoma (CCA) therapy. However, it remains difficult to predict which ICI will be effective for individual patients. Therefore, the aim of this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5340ce172736b9d215c163420c585b2d
https://pure.eur.nl/en/publications/ff7205ea-851c-4c52-af5e-7b7ea9523b03
https://pure.eur.nl/en/publications/ff7205ea-851c-4c52-af5e-7b7ea9523b03
